These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 35016642

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decreased IgA binding levels were accompanied by increased IgG sialylation in IgA nephropathy.
    Liu Y, Chen H, Li H, Wang F, Xing Y, Wu Z, Li W, Jia J, Yan T.
    Clin Nephrol; 2024 Aug; 102(2):89-96. PubMed ID: 38856027
    [Abstract] [Full Text] [Related]

  • 3. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
    Zhao YF, Zhu L, Liu LJ, Shi SF, Lv JC, Zhang H.
    BMC Nephrol; 2017 Sep 29; 18(1):301. PubMed ID: 28969604
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC.
    Kidney Int; 2011 Dec 29; 80(12):1352-63. PubMed ID: 21866091
    [Abstract] [Full Text] [Related]

  • 6. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
    Zachova K, Jemelkova J, Kosztyu P, Ohyama Y, Takahashi K, Zadrazil J, Orsag J, Matousovic K, Galuszkova D, Petejova N, Mestecky J, Raska M.
    J Am Soc Nephrol; 2022 May 29; 33(5):908-917. PubMed ID: 35115327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.
    Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J.
    Kidney Int; 1997 Aug 29; 52(2):509-16. PubMed ID: 9264010
    [Abstract] [Full Text] [Related]

  • 11. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.
    Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J.
    Kidney Int; 2005 Feb 29; 67(2):504-13. PubMed ID: 15673298
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
    Zhang K, Li Q, Zhang Y, Shang W, Wei L, Li H, Gao S, Yan T, Jia J, Liu Y, Lin S.
    Kidney Blood Press Res; 2019 Feb 29; 44(5):1196-1206. PubMed ID: 31574506
    [Abstract] [Full Text] [Related]

  • 14. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, Fatima H, Julian BA, Novak J.
    J Am Soc Nephrol; 2019 Oct 29; 30(10):2017-2026. PubMed ID: 31444275
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.
    Schmitt R, Ståhl AL, Olin AI, Kristoffersson AC, Rebetz J, Novak J, Lindahl G, Karpman D.
    J Immunol; 2014 Jul 01; 193(1):317-26. PubMed ID: 24850720
    [Abstract] [Full Text] [Related]

  • 18. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
    Xu LX, Zhao MH.
    Kidney Int; 2005 Jul 01; 68(1):167-72. PubMed ID: 15954905
    [Abstract] [Full Text] [Related]

  • 19. Molecular Insights into the Pathogenesis of IgA Nephropathy.
    Robert T, Berthelot L, Cambier A, Rondeau E, Monteiro RC.
    Trends Mol Med; 2015 Dec 01; 21(12):762-775. PubMed ID: 26614735
    [Abstract] [Full Text] [Related]

  • 20. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
    Stuchlova Horynova M, Vrablikova A, Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian BA, Renfrow MB, Novak J, Raska M.
    Nephrol Dial Transplant; 2015 Feb 01; 30(2):234-8. PubMed ID: 25281698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.